Serum free light chain assays are included in a range of International and National guidelines including:
International Myeloma Working Group
The National Comprehensive Cancer Network
European Society of Medical Oncology
International Kidney and Monoclonal Gammopathy Research Group
*All data used in these guidelines was generated using the Freelite® free light chain assay.
It cannot be assumed that other commercially available free light chain assays will give compliance with these guidelines
International Myeloma Working Group Guidelines
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.
Rajkumar SV, et al. Lancet Oncology 2014; 15:e538-e548
International Myeloma Working Group recommendations for global myeloma care.
Ludwig H, et al. Leukemia 2014; 28:981-992
New Criteria for Response to Treatment in Immunoglobulin Light Chain Amyloidosis Based on Free Light Chain Measurement and Cardiac Biomarkers: Impact on Survival Outcomes.
Palladini, et al. J Clin Onc 2012; 30:4541-4549
Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1.
Rajkumar SV, et al, Blood 2011; 117:4691-4695
Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management.
Kyle RA, et al. Leukemia 2010; 24:1121-1127
International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders.
Dispenzieri A, et al. Leukemia 2009; 23:215-224
International uniform response criteria for multiple myeloma.
Durie BGM, et al. Leukemia 2006; 20:1467-1473